We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Safety of Hepatitis C Viral Protease Inhibitors in Compensated Cirrhotics: Lingering Concerns Put to Rest?
- Authors
Kiser, Jennifer J
- Abstract
The article offers information on concern related to safety of Hepatitis C viral (HCV) protease inhibitors in compensated cirrhotics. Topics discussed include information on analysis of the safety, efficacy, and pharmacokinetics of glecaprevir and pibrentasvir in compensated cirrhotics; informartion on preponderance of evidence indicates that HCV PIs cause concentration-dependent hepatotoxicity; and need to monitor liver function tests, bilirubin, and signs and symptoms of decompensation.
- Subjects
HEPATOTOXICOLOGY -- Risk factors; CHRONIC kidney failure; CHRONIC hepatitis C; DRUG tolerance; CIRRHOSIS of the liver; TREATMENT effectiveness; GENOTYPES; PATIENT safety; ALANINE aminotransferase; BILIRUBIN; DISEASE complications
- Publication
Clinical Infectious Diseases, 2019, Vol 69, Issue 10, p1665
- ISSN
1058-4838
- Publication type
Article
- DOI
10.1093/cid/ciz025